25 Jan Johnson & Johnson releases Q4 2021 report. Revenue was worse than expected, but the company made a good forecast for 2022. By the end of the day stock J&J grew up on 3%, to 168 $. Financial results Compared to the fourth quarter of 2020: revenue — 24.8 billion (+10,4%), analyst expectations - $25.3 billion; adjusted earnings per share — 2,13 (+14,5%), analysts' expectations 2,12 $. And here is how sales in operating segments have changed. Pharmaceutical - drugs and vaccines - $14.3 billion (+16,5%). Revenue in this segment grew largely due to sales of the COVID-19 vaccine to various countries around the world. For the quarter, this revenue amounted to $ 1.6 billion, or 6,5% of total revenue. Medical Devices - medical devices - $6.9 billion (+4,1%). Here, sales grew weakly due to a shortage of medical staff and postponed elective surgeries due to the pandemic.. Consumer Health - OTC medicines and hygiene products - $3.7 billion (+1,1%). In this segment, sales have suffered due to a shortage of raw materials, workforce and disruptions in logistics. Until the end of 2023 J&J plans to spin off its slow-growing consumer business into a separate public company. The name of the company will be announced in mid-2022. Sales J&J for 2021, $bn Segment Revenue Pharmaceutical 52,1 (+14,3%) Medical Devices 27,1 (+17,9%) Consumer Health 14,6 (+4,1) Total 93,8 (+13,6%) Выручка Баланс и потоки По данным на конец 2021 года, Debt J&J was $34 billion, and the volume of liquid money - 32 billion. As a result, the company's net debt is only 2 billion - the minimum in the last five years, with the letter J&J. Free cash flow last year was $20 billion. Of these, 11 billion J&J returned to its shareholders in the form of dividends. In 2022, the company plans to use free money also for acquisitions. …
Quarterly revenue J&J rose to 10% thanks to vaccine sales Read more